AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 7 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) provided an update of data from the phase II Theratope vaccine colorectal study of 20 patients.
A Kaplan-Meier Survival and Time to Disease Progression Curve of the 20 colorectal cancer patients who received combination chemotherapy plus Theratope in the featured study showed a median survival of 17.8 months and a median time to disease progression of 8.4 months. The median time to disease progression remains unchanged from data reported in June 2003.
The trial was designed to evaluate the safety of Theratope in patients with metastatic colorectal cancer, as well as to evaluate the ability of the vaccine to induce an immune response in patients when given in combination with first-line chemotherapy. Although the trial was not designed to evaluate survival benefit in these small numbers, it indicates a positive trend in the patients followed.
Biomira had reported earlier that the phase II study of Theratope in the treatment of metastatic colorectal cancer showed that patients are capable of mounting an immune response to the investigational vaccine while receiving concurrent chemotherapy.
"Colorectal cancer is the third most common cancer found in men and women in North ...
Source: HighBeam Research, Phase II colorectal vaccine trial results updated.